» Articles » PMID: 38004612

Anti-Obesity Drug Delivery Systems: Recent Progress and Challenges

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2023 Nov 25
PMID 38004612
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity has reached an epidemic proportion in the last thirty years, and it is recognized as a major health issue in modern society now with the possibility of serious social and economic consequences. By the year 2030, nearly 60% of the global population may be obese or overweight, which emphasizes a need for novel obesity treatments. Various traditional approaches, such as pharmacotherapy and bariatric surgery, have been utilized in clinical settings to treat obesity. However, these methods frequently show the possibility of side effects while remaining ineffective. There is, therefore, an urgent need for alternative obesity treatments with improved efficacy and specificity. Polymeric materials and chemical strategies are employed in emerging drug delivery systems (DDSs) to enhance therapy effectiveness and specificity by stabilizing and controlling the release of active molecules such as natural ingredients. Designing DDSs is currently a top priority research objective with an eye towards creating obesity treatment approaches. In reality, the most recent trends in the literature demonstrate that there are not enough in-depth reviews that emphasize the current knowledge based on the creation and design of DDSs for obesity treatment. It is also observed in the existing literature that a complex interplay of different physical and chemical parameters must be considered carefully to determine the effectiveness of the DDSs, including microneedles, for obesity treatment. Additionally, it is observed that these properties depend on how the DDS is synthesized. Although many studies are at the animal-study stage, the use of more advanced DDS techniques would significantly enhance the development of safe and efficient treatment approaches for obese people in the future. Considering these, this review provides an overview of the current anti-obesity treatment approaches as well as the conventional anti-obesity therapeutics. The article aims to conduct an in-depth discussion on the current trends in obesity treatment approaches. Filling in this knowledge gap will lead to a greater understanding of the safest ways to manage obesity.

Citing Articles

Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions.

Subramaniyan V, Hanim Y Int J Obes (Lond). 2025; .

PMID: 40016558 DOI: 10.1038/s41366-025-01729-1.


Effect of gold nanoparticles treatment on rats-induced obesity by evaluating body-composition directly and indirectly via bioelectric impedance analysis.

Selima R, Saleem I, Shawki M, Darwish A, Yehia M, Mohamed E Sci Rep. 2025; 15(1):4942.

PMID: 39929902 PMC: 11811030. DOI: 10.1038/s41598-025-87971-z.


Succinic Acid Improves the Metabolism of High-Fat Diet-Induced Mice and Promotes White Adipose Browning.

Yang Y, Luo L, Li Y, Shi X, Li C, Chai J Nutrients. 2024; 16(22).

PMID: 39599615 PMC: 11597198. DOI: 10.3390/nu16223828.


Nanomaterial-Enhanced Microneedles: Emerging Therapies for Diabetes and Obesity.

Abbasi M, Boka D, DeLoit H Pharmaceutics. 2024; 16(10).

PMID: 39458672 PMC: 11510597. DOI: 10.3390/pharmaceutics16101344.


Mechanisms Underlying the Therapeutic Effects of Nicotinamide Mononucleotide in Treating High-fat Diet-induced Hypertrophic Cardiomyopathy based on GEO Datasets, Network Pharmacology, and Molecular Docking.

Han Y, Wang L, Zhang Y, Zhou A, Wang Z, Dong W Curr Pharm Des. 2024; 30(38):3054-3070.

PMID: 39171590 DOI: 10.2174/0113816128311226240730080713.

References
1.
Liechty W, Kryscio D, Slaughter B, Peppas N . Polymers for drug delivery systems. Annu Rev Chem Biomol Eng. 2012; 1:149-73. PMC: 3438887. DOI: 10.1146/annurev-chembioeng-073009-100847. View

2.
Feng Q, Tong R . Anticancer nanoparticulate polymer-drug conjugate. Bioeng Transl Med. 2018; 1(3):277-296. PMC: 5689533. DOI: 10.1002/btm2.10033. View

3.
Liao L, Liu J, Dreaden E, Morton S, Shopsowitz K, Hammond P . A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J Am Chem Soc. 2014; 136(16):5896-9. PMC: 4105175. DOI: 10.1021/ja502011g. View

4.
Schmidt B . Hydrophilic Polymers. Polymers (Basel). 2019; 11(4). PMC: 6523788. DOI: 10.3390/polym11040693. View

5.
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View